Life Sciences Hedge Funds May Have Moved Past One of Their Worst Stretches

Still, many funds will need several years of strong gains to return to their high-water marks.


Andrey Rudakov/Bloomberg

In January, the majority of life sciences and biopharma hedge funds extended their profitable monthly string to three months.

This is significant as most of the funds went through several years of losses. Many observers now believe that the strategy just might have moved past its worst stretch in recent memory.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.